Mumbai-based Entod Pharma, known for its ophthalmology and dermatology products, is currently undertaking groundbreaking innovations across its speciality divisions. Apart from its eye drops for treating myopia in children from age 6 to 12, the company has developed an advanced collagen-based transdermal gel serum for multi-layered skin regeneration.
Talking about the need for more R&D investments, Nikkhil K Masurkar, CEO of Entod Pharmaceuticals, said, “We will not achieve it until we innovate, and we need to have branded and patented products which we then sell globally. So, we have to invest in R&D. We have to prepare a 2030-plus market and need innovative products which are not even in the US or regulated markets.”
The company plans to venture into the mental health segment, focusing on neuropsychiatry. Masurkar added, “For us to enter mental health, neuropsychiatric becomes the natural progression. We have engaged with neuro-ophthalmologists for the same. There are some ophthalmic medicines which can be used for neurological conditions like migraine.”
Mentioning the controversy related to the PresVu eye drop that eliminates the dependency on reading glasses for those suffering from presbyopia, Masurkar said, “The eye drop has been approved between March and April this year, and we have already launched the product in the market in April.”
According to him, a wrong message was spread to the market quickly, which led to the suspension. He added, “Why should the pharma company bear the brunt of public misuse?”
Sanjiv Das
sanjiv.das@mmactiv.com
